• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by TFF Pharmaceuticals Inc. (Amendment)

    2/14/22 4:10:37 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TFFP alert in real time by email
    SC 13G/A 1 tm226221d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    TFF Pharmaceuticals, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    87241J104
    (CUSIP Number)
     
    December 31, 2021
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP No. 87241J104

     

    1 Names of reporting persons
    Corriente Advisors, LLC
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) ¨
    3 SEC use only
     
    4 Citizenship or place of organization
    Delaware

    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:

     

    5 Sole voting power
    0
    6 Shared voting power
    0
    7 Sole dispositive power
    0
    8 Shared dispositive power
    0

    9 Aggregate amount beneficially owned by each reporting person
    0
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    0.0%
    12 Type of reporting person (see instructions)
    OO

     

    2

     

     

    CUSIP No. 87241J104

     

    1 Names of reporting persons
    Corriente Master Fund II, LP
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) ¨
    3 SEC use only
     
    4 Citizenship or place of organization
    Cayman Islands

    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power
    0
    7 Sole dispositive power
    0
    8 Shared dispositive power
    0

    9 Aggregate amount beneficially owned by each reporting person
    0
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ☐
    11 Percent of class represented by amount in Row (9)
    0.0%
    12 Type of reporting person (see instructions)
    PN

     

    3

     

     

    CUSIP No. 87241J104

     

    1 Names of reporting persons
    Mark L. Hart III
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) ¨
    3 SEC use only
     
    4 Citizenship or place of organization
    United States of America

    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:

     

    5 Sole voting power
    0
    6 Shared voting power
    0
    7 Sole dispositive power
    0
    8 Shared dispositive power
    0

    9 Aggregate amount beneficially owned by each reporting person
    0
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    0.0%
    12 Type of reporting person (see instructions)
    IN

     

    4

     

     

    Explanatory Note

     

    This Amendment No. 1 (this “Amendment”) amends, in its entirety, the statement on Schedule 13G originally filed on February 16, 2021 (the “Schedule 13G”) by the Reporting Persons (defined below). This Amendment reflects that, as of the date hereof, each Reporting Person has ceased to be the beneficial owner of more than 5% of any class of securities of the Issuer. This Amendment is the final amendment to the Schedule 13G.

     

    Item 1(a) Name of issuer:

     

    TFF Pharmaceuticals, Inc.

     

    Item 1(b) Address of issuer’s principal executive offices:

     

    2600 Via Fortuna, Suite 360, Austin, Texas 78746

     

    Item 2(a) Name of person filing:

     

    This Amendment is being filed on behalf of each of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”)

     

    i)Corriente Advisors, LLC (“Corriente Advisors”);

     

    ii)Corriente Master Fund II, LP (“Corriente Master Fund II”); and

     

    iii)Mark L. Hart III (“Mr. Hart”).

     

    This Amendment relates to shares of common stock of the Issuer, par value $0.001 per share (“Shares”), that were previously directly held by Corriente Master Fund II. Corriente Advisors acts as an investment adviser to, and manages investment and trading accounts of, Corriente Master Fund II. Corriente Advisors may be deemed to indirectly beneficially own securities held by Corriente Master Fund II. Mr. Hart is the Chairman and Chief Executive Officer of Corriente Advisors. Mr. Hart may be deemed to indirectly beneficially own securities held by Corriente Master Fund II. As of the date hereof, none of the Reporting Persons beneficially own any Shares or warrants or options to purchase Shares.

     

    Each Reporting Person declares that neither the filing of this Amendment or the Schedule 13G nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act) with any other person as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any syndicate or group with respect to the Issuer or any securities of the Issuer.

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    The address of the principal business office of each of the Reporting Persons is 1401 Foch St, Suite 100, Fort Worth, TX 76107.

     

    Item 2(c) Citizenship:

     

    i)Corriente Advisors is a Delaware limited liability company;

     

      ii) Corriente Master Fund II is a Cayman Islands limited partnership; and

     

      iii) Mr. Hart is a citizen of the United States of America.

     

    5

     

     

    Item 2(d) Title of Class of Securities:

     

    Common Stock, par value $0.001 per share

     

    Item 2(e) CUSIP No.:

     

    87241J104

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

     

      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c) ¨ Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); 

     

      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); 

     

      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); 

     

      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 

     

      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); 

     

      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); 

     

      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). 

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________.

     

    6

     

     

    Item 4. Ownership

     

    As of the date hereof, for each of the Reporting Persons:

     

    (a)Amount beneficially owned:   0
    (b)Percent of class:   0.0%
    (c)Number of shares as to which such person has:
    (i)Sole power to vote or direct the vote: 0
    (ii)Shared power to vote or direct the vote: 0
    (iii)Sole power to dispose or to direct the disposition of: 0
    (iv)Shared power to dispose or to direct the disposition of: 0

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

    CORRIENTE ADVISORS, LLC  
       
    /s/ Matthew Gilman  
    Chief Financial Officer  

     

    CORRIENTE MASTER FUND II, LP  
       
    /s/ Matthew Gilman  
    Chief Financial Officer of Corriente Advisors, LLC, the Investment Manager of Corriente Master Fund II, LP  

     

    MARK L. HART III  
       
    /s/ Mark L. Hart III  
       

     

    8

     

     

    EXHBIT INDEX

      

    Exhibit Page No.
    A.  Joint Filing Agreement 10

     

    9

     

    Get the next $TFFP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TFFP

    DatePrice TargetRatingAnalyst
    5/19/2022$22.00Buy
    H.C. Wainwright
    More analyst ratings

    $TFFP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Weisman Harlan F was granted 27,480 shares, increasing direct ownership by 3% to 842,095 units (SEC Form 4)

    4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)

    7/8/24 5:46:27 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lee Catherine Chai-Zon was granted 1,583 shares (SEC Form 4)

    4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)

    7/8/24 5:44:38 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mills Robert S was granted 3,165 shares, increasing direct ownership by 6% to 59,145 units (SEC Form 4)

    4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)

    7/8/24 5:44:15 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TFFP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on TFF Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $22.00

    5/19/22 9:05:50 AM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright reiterated coverage on TFF Pharmaceuticals with a new price target

    HC Wainwright reiterated coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $37.00 from $31.00 previously

    3/11/21 8:08:25 AM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on TFF Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $37.00 from $31.00 previously

    3/5/21 6:29:56 AM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TFFP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration

    FOXBOROUGH, Mass., Feb. 6, 2025 /PRNewswire/ -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) today announced that the Company has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to voluntarily delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. The Company expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of its Common Stock on or about February 16, 2025. The removal of the Common Stock from Nasdaq will be effective 10 days after the filing of the Form 25. The Company has made no arrangements for

    2/6/25 4:05:00 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TFF Pharmaceuticals Announces It Will Wind Down Operations

    FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, Chief Financial Officer, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of office

    11/14/24 4:15:00 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

    FORT WORTH, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (NASDAQ:TFFP) (the "Company" or "TFF Pharmaceuticals"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, announces positive preclinical data published in the Journal of Drug Delivery Science and Technology further validating the Company's TFF technology as superior approach to formulate dry powders for pulmonary drug delivery. The study demonstrates the superiority of TFF inhalational dry powders over jet-milling and spray-drying technologies in a rat model, with enhanced uniform drug

    9/26/24 7:00:00 AM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TFFP
    SEC Filings

    View All

    SEC Form DEF 14A filed by TFF Pharmaceuticals Inc.

    DEF 14A - TFF Pharmaceuticals, Inc. (0001733413) (Filer)

    12/23/24 6:50:03 AM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by TFF Pharmaceuticals Inc.

    PRE 14A - TFF Pharmaceuticals, Inc. (0001733413) (Filer)

    12/11/24 4:05:37 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TFF Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - TFF Pharmaceuticals, Inc. (0001733413) (Filer)

    12/10/24 4:05:34 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TFFP
    Leadership Updates

    Live Leadership Updates

    View All

    TFF Pharmaceuticals Announces It Will Wind Down Operations

    FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, Chief Financial Officer, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of office

    11/14/24 4:15:00 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors

    FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors. "I am pleased to welcome Thomas King to our Board of Directors," said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. "Tom is an exceptionally accomplished executive who has held leadership positions at life sciences companies over the last three decades. In addition, his extensive board experience will p

    12/13/23 8:00:00 AM ET
    $ACHV
    $TFFP
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations

    TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors

    FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Michael Patane, Ph.D., to its Board of Directors. "I am pleased to welcome Dr. Patane to our Board of Directors," said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. "Mike's career spans over two decades of leadership experience in drug discovery and development, and he has demonstrated an extraordinary ability to turn scientific success into corp

    11/30/23 8:00:00 AM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TFFP
    Financials

    Live finance-specific insights

    View All

    TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

    Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to Demonstrate Antifungal Activity and a Favorable Safety and Tolerability Profile TFF TAC Program Prioritized Based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and Substantial Market Opportunity Company to Hold Conference Call and Webcast Today at 4:30 pm ET FORT WORTH, Texas , March 27, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing

    3/27/24 4:01:00 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TFF Pharmaceuticals Announces Update on Clinical Programs

    Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and Substantial Market Opportunity Company to Evaluate Strategic Options for TFF VORI, including Partnerships, Collaborations, and Grants following Positive Data from Phase 2 Study and the Expanded Access Program (EAP) Company to Discuss Clinical Updates on TFF TAC and TFF VORI on Wednesday, March 27, 2024 at 4:30 pm ET FORT WORTH, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing an

    3/20/24 9:03:36 AM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

    Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause mortality, no invasive pulmonary aspergillosis (IPA)-related mortality, and no TFF VORI discontinuations due to an adverse event (AE) Successful transition of all four patients from oral tacrolimus to TFF TAC, leading to significant lowering of tacrolimus blood levels with no clinical evidence of acute rejection; all patients who completed Part A (study treatment period) of the trial chose to remain on TFF TAC and advance to Part B (extension study) TFF TAC was well tolerated, with no mortality a

    12/19/23 6:00:00 AM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TFFP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TFF Pharmaceuticals Inc.

    SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

    11/19/24 4:05:58 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by TFF Pharmaceuticals Inc.

    SC 13G - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

    11/14/24 3:37:45 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by TFF Pharmaceuticals Inc.

    SC 13G - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

    5/8/24 5:13:05 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care